Moderna Net Worth
Moderna Net Worth Breakdown | MRNA |
Moderna Net Worth Analysis
Moderna's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Moderna's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Moderna's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Moderna's net worth analysis. One common approach is to calculate Moderna's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Moderna's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Moderna's net worth. This approach calculates the present value of Moderna's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Moderna's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Moderna's net worth. This involves comparing Moderna's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Moderna's net worth relative to its peers.
To determine if Moderna is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Moderna's net worth research are outlined below:
| Moderna had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 3.24 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.62 B). | |
| Moderna currently holds about 8.35 B in cash with (3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73. | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: MRNA Stock Jumps on CDCs Revised RSV Vaccine Recommendations |
Moderna uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Moderna. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moderna's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Moderna Target Price Consensus
Moderna target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Moderna's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 27 | Buy |
Most Moderna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Moderna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Moderna, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationModerna Target Price Projection
Moderna's current and average target prices are 30.49 and 46.96, respectively. The current price of Moderna is the price at which Moderna is currently trading. On the other hand, Moderna's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Moderna Target Price
Know Moderna's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Moderna is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moderna backward and forwards among themselves. Moderna's institutional investor refers to the entity that pools money to purchase Moderna's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Flagship Ventures Management, Inc. | 2025-03-31 | 4.6 M | Two Sigma Investments Llc | 2025-03-31 | 4.5 M | Norges Bank | 2024-12-31 | 3.9 M | Two Sigma Advisers, Llc | 2025-03-31 | 3.8 M | Ubs Asset Mgmt Americas Inc | 2025-03-31 | 3.6 M | Jane Street Group Llc | 2025-03-31 | 3.6 M | Voloridge Investment Management, Llc | 2025-03-31 | 3.3 M | Goldman Sachs Group Inc | 2025-03-31 | 3.2 M | Banque Pictet & Cie Sa | 2025-03-31 | 3.1 M | Vanguard Group Inc | 2025-03-31 | 40.4 M | Blackrock Inc | 2025-03-31 | 27.2 M |
Follow Moderna's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.79 B.Project Moderna's profitablity
The company has Profit Margin (PM) of (1.06) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (9.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $9.72.When accessing Moderna's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Moderna's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Moderna's profitability and make more informed investment decisions.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.
Evaluate Moderna's management efficiency
Moderna has return on total asset (ROA) of (0.1584) % which means that it has lost $0.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2934) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Total Assets are forecasted to decline to about 9.6 B.Leadership effectiveness at Moderna is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 2.0904 | Revenue | Quarterly Revenue Growth (0.35) | Revenue Per Share 8.252 | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephane Bancel over three months ago Acquisition by Stephane Bancel of 357065 shares of Moderna at 30.96 subject to Rule 16b-3 | ||
Hoge Stephen over three months ago Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3 | ||
James Mock over six months ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | ||
Noubar Afeyan over six months ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3 | ||
Noubar Afeyan over a year ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3 | ||
James Mock over a year ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3 |
Moderna Earnings Estimation Breakdown
The calculation of Moderna's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Moderna is estimated to be -1.8162 with the future projection ranging from a low of -2.4995 to a high of -1.25. Please be aware that this consensus of annual earnings estimates for Moderna is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.5 Lowest | Expected EPS | -1.25 Highest |
Moderna Earnings Projection Consensus
Suppose the current estimates of Moderna's value are higher than the current market price of the Moderna stock. In this case, investors may conclude that Moderna is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Moderna's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of September 2025 | Current EPS (TTM) | |
| 26 | 72.36% | 0.0 | -1.8162 | -8.73 |
Moderna Earnings per Share Projection vs Actual
Actual Earning per Share of Moderna refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Moderna predict the company's earnings will be in the future. The higher the earnings per share of Moderna, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Moderna Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Moderna, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Moderna should always be considered in relation to other companies to make a more educated investment decision.Moderna Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-04-30 | 2025-03-31 | -3.03 | -2.52 | 0.51 | 16 | ||
2025-02-20 | 2024-12-31 | -2.7599 | -2.91 | -0.1501 | 5 | ||
2024-11-07 | 2024-09-30 | -1.9 | 0.03 | 1.93 | 101 | ||
2024-08-01 | 2024-06-30 | -3.38 | -3.33 | 0.05 | 1 | ||
2024-05-02 | 2024-03-31 | -3.58 | -3.07 | 0.51 | 14 | ||
2024-02-22 | 2023-12-31 | -0.97 | 0.55 | 1.52 | 156 | ||
2023-11-02 | 2023-09-30 | -1.93 | -9.53 | -7.6 | 393 | ||
2023-08-03 | 2023-06-30 | -4.04 | -3.62 | 0.42 | 10 | ||
2023-05-04 | 2023-03-31 | -1.77 | 0.19 | 1.96 | 110 | ||
2023-02-23 | 2022-12-31 | 4.68 | 3.61 | -1.07 | 22 | ||
2022-11-03 | 2022-09-30 | 3.29 | 2.53 | -0.76 | 23 | ||
2022-08-03 | 2022-06-30 | 4.55 | 5.24 | 0.69 | 15 | ||
2022-05-04 | 2022-03-31 | 5.21 | 8.58 | 3.37 | 64 | ||
2022-02-24 | 2021-12-31 | 9.9 | 11.29 | 1.39 | 14 | ||
2021-11-04 | 2021-09-30 | 9.05 | 7.7 | -1.35 | 14 | ||
2021-08-05 | 2021-06-30 | 5.96 | 6.46 | 0.5 | 8 | ||
2021-05-06 | 2021-03-31 | 2.39 | 2.84 | 0.45 | 18 | ||
2021-02-25 | 2020-12-31 | -0.35 | -0.69 | -0.34 | 97 | ||
2020-10-29 | 2020-09-30 | -0.43 | -0.59 | -0.16 | 37 | ||
2020-08-05 | 2020-06-30 | -0.35 | -0.31 | 0.04 | 11 | ||
2020-05-07 | 2020-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2020-02-26 | 2019-12-31 | -0.42 | -0.37 | 0.05 | 11 | ||
2019-11-06 | 2019-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2019-08-07 | 2019-06-30 | -0.44 | -0.41 | 0.03 | 6 | ||
2019-05-08 | 2019-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2019-03-06 | 2018-12-31 | -0.36 | -1.78 | -1.42 | 394 | ||
2018-12-07 | 2018-09-30 | 0 | -0.52 | -0.52 | 0 |
Moderna Corporate Management
| Melanie MBA | Chief Officer | Profile | |
| Stephane Bancel | CEO Director | Profile | |
| Dave Johnson | Chief Officer | Profile | |
| Lavina CFA | Senior Relations | Profile | |
| Noubar Afeyan | Independent CoFounder | Profile | |
| Allison MD | Senior Development | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (8.73) | Revenue Per Share 8.252 | Quarterly Revenue Growth (0.35) | Return On Assets (0.16) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.